BioSpace News Archive

Chambersburg Hospital received the Healthgrades Distinguished Hospital Award for Clinical Excellence™ (2017 and 2018) while also being named one of Healthgrades America’s 100 Best Hospitals™ for Coronary Intervention, Orthopedic Surgery, Pulmonary Care, and Critical Care in 2018

Monte Nido & Affiliates announces the opening of Clementine, the newest eating disorder treatment center exclusively for adolescent girls aged twelve to seventeen in Fairfax County, Virginia. Clementine will debut its newest residential treatment center this October.

NxGen MDx announced a new partnership with Answer Health on Demand, which enables patients to see a genetic counselor or doctor using secure audio and video via smartphone application, tablet, or computer.

Pulse Biosciences, Inc. announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 34,250 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 17, 2018.

QST Consultations, Ltd. announced today the appointment of Dr. Phil Doren as Chief Executive Officer and Member of the Board of Directors. Dr. John Quiring, who founded the company has been operating as interim CEO since January.

Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at Children’s Hospital of Philadelphia and Chief of the Section of Cellular Therapy and Transplant at the Children’s Hospital of Philadelphia (CHOP) joined the Company’s Clinical Advisory Board

Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.9 million, or $0.41 per diluted share, on net sales of $39.2 million for the quarter ended June 30, 2018.

Elanco Animal Health Incorporated, a subsidiary of Eli Lilly and Company (NYSE:LLY), announced today the pricing of its initial public offering (IPO) of 62.9 million shares of its common stock at a price to the public of $24.00 per share.

Revelations by Women Sexually Assaulted By Their Doctors Spurred Transparency

GI Dynamics, Inc. is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company